JPWO2022094106A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022094106A5
JPWO2022094106A5 JP2023524162A JP2023524162A JPWO2022094106A5 JP WO2022094106 A5 JPWO2022094106 A5 JP WO2022094106A5 JP 2023524162 A JP2023524162 A JP 2023524162A JP 2023524162 A JP2023524162 A JP 2023524162A JP WO2022094106 A5 JPWO2022094106 A5 JP WO2022094106A5
Authority
JP
Japan
Prior art keywords
seq
encoding
amino acid
acid sequence
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547832A5 (https=
JP2023547832A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057084 external-priority patent/WO2022094106A1/en
Publication of JP2023547832A publication Critical patent/JP2023547832A/ja
Publication of JP2023547832A5 publication Critical patent/JP2023547832A5/ja
Publication of JPWO2022094106A5 publication Critical patent/JPWO2022094106A5/ja
Pending legal-status Critical Current

Links

JP2023524162A 2020-10-28 2021-10-28 眼の適応症に対するベクター化抗TNF-α抗体 Pending JP2023547832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106832P 2020-10-28 2020-10-28
US63/106,832 2020-10-28
PCT/US2021/057084 WO2022094106A1 (en) 2020-10-28 2021-10-28 VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS

Publications (3)

Publication Number Publication Date
JP2023547832A JP2023547832A (ja) 2023-11-14
JP2023547832A5 JP2023547832A5 (https=) 2024-10-29
JPWO2022094106A5 true JPWO2022094106A5 (https=) 2024-10-29

Family

ID=78819630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524162A Pending JP2023547832A (ja) 2020-10-28 2021-10-28 眼の適応症に対するベクター化抗TNF-α抗体

Country Status (12)

Country Link
US (1) US20230391864A1 (https=)
EP (1) EP4236999A1 (https=)
JP (1) JP2023547832A (https=)
KR (1) KR20230093437A (https=)
CN (1) CN116528892A (https=)
AR (1) AR123948A1 (https=)
AU (1) AU2021371307A1 (https=)
CA (1) CA3195967A1 (https=)
IL (1) IL302279A (https=)
MX (1) MX2023004806A (https=)
TW (1) TW202233841A (https=)
WO (1) WO2022094106A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3247507A1 (en) * 2022-04-06 2023-10-12 Regenxbio Inc. PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION
WO2024003578A1 (en) * 2022-07-01 2024-01-04 The University Of Bristol Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
EP4627095A2 (en) * 2022-11-28 2025-10-08 Siren Biotechnology, Inc. Gene therapy vectors for treatment of cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
ATE544776T1 (de) 1994-12-29 2012-02-15 Massachusetts Inst Technology Chimäre dna-bindeproteine
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
US6117680A (en) 1997-08-26 2000-09-12 Ariad Gene Therapeutics, Inc. Compositions and methods for regulation of transcription
CA2303482A1 (en) 1997-08-27 1999-03-04 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
AU766513B2 (en) 1998-02-13 2003-10-16 Board Of Trustees Of The Leland Stanford Junior University Novel dimerizing agents, their production and use
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US7183969B2 (en) 2004-12-22 2007-02-27 Raytheon Company System and technique for calibrating radar arrays
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
EP3257937B1 (en) 2008-02-19 2022-08-03 uniQure IP B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
ES2724122T3 (es) 2009-04-30 2019-09-06 Univ Pennsylvania Composiciones para dirigir células de las vías respiratorias de conducción que comprenden construcciones de virus adenoasociado
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
KR102413498B1 (ko) 2013-04-20 2022-06-24 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
JP6665466B2 (ja) 2015-09-26 2020-03-13 日亜化学工業株式会社 半導体発光素子及びその製造方法
WO2017070491A1 (en) 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations
IL319993A (en) * 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
JP7046828B2 (ja) * 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
WO2018056268A1 (ja) * 2016-09-20 2018-03-29 参天製薬株式会社 炎症性眼疾患の治療及び/又は予防剤
AU2018227483A1 (en) * 2017-02-28 2019-09-12 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos

Similar Documents

Publication Publication Date Title
EP3717636B1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
EP4349852A1 (en) Recombinant adeno-associated virus having variant capsid, and application thereof
JP2025039615A (ja) 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
JP2022530006A (ja) 完全ヒト翻訳後修飾抗体による治療剤
JP2020048571A5 (https=)
US20230381341A1 (en) Adeno-associated viruses for ocular delivery of gene therapy
JP2008506389A (ja) Aavベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
WO2015035190A1 (en) Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
JP2018526003A (ja) イヌの癌を治療するためのキメラaav−抗vegf
US20150182638A1 (en) Virus-mediated delivery of bevacizumab for therapeutic applications
WO2021255590A1 (en) An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
JP2017506230A (ja) 黄斑変性を処置し、予防するための組成物および方法
WO2021255589A1 (en) An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
CN121569038A (zh) 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法
CN116981485A (zh) 使用双重病毒载体系统递送抗体
JP2023547832A (ja) 眼の適応症に対するベクター化抗TNF-α抗体
US20240092885A1 (en) Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
CN119053692A (zh) 用于提高rAAV滴度的HEK293悬浮平台的优化
JPWO2022094106A5 (https=)
CN117242183A (zh) 用于治疗与血管生成相关的眼部疾病的组合物和方法
JPWO2021243085A5 (https=)
TW202417633A (zh) 用於眼適應症之載體化抗TNF-α抑制劑
JPWO2022094295A5 (https=)
WO2026021520A1 (zh) 一种新型基因治疗药物
CN119264217A (zh) 具有变异衣壳蛋白的腺相关病毒及其应用